Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 5/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790812 | 0.76 | TNKS (0.59) | KDM4ELMNACYP2C9CYP2C19PARP1 | |
| SCHEMBL28049891 | 0.75 | PARP1 (0.71) | KDM4ELMNACYP2C9CYP2C19PARP1 | |
| SCHEMBL4852668 | 0.74 | PARP1 (0.69) | CYP2C9CYP2C19PARP1PARP2PDE10A | |
| SCHEMBL29735862 | 0.74 | PARP1 (0.83) | CYP2C9CYP2C19PARP1PARP2MAPT | |
| SCHEMBL15575028 | 0.74 | PARP1 (0.83) | CYP2C9CYP2C19PARP1PARP2MAPT | |
| SCHEMBL30495504 | 0.74 | PARP1 (0.65) | CYP2C9CYP2C19PARP1PARP2MAPT | |
| SCHEMBL6795780 | 0.74 | PARP1 (0.61) | PARP1PARP2ALDH1A1TSHRPDE10A | |
| SCHEMBL30176852 | 0.74 | PARP1 (0.73) | LMNAPARP1PARP2ALDH1A1PDE10A | |
| SCHEMBL23073611 | 0.74 | PARP1 (0.73) | KDM4ELMNACYP2C9CYP2C19PARP1 | |
| SCHEMBL16404338 | 0.73 | PDE10A (0.84) | KDM4ELMNAPARP1PARP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940407-B1 | N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100267633-A1 | N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-10-21 | — | — | US | disclosed |
| EP-1940407-A2 | N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007038444-A3 | N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007038444-A2 | N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267633-A1 | N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators | AR, FSHR, SHBG | KDM4E 521/4885LMNA 2827/4885CYP2C9 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.